AMCo acquires Australian company Boucher & Muir

15 July 2015

British niche pharmaceutical business AMCo has acquired the Australian family-owned pharmaceutical company, Boucher & Muir (BNM). Financial terms of the transaction were not disclosed.

BNM was set up in 1957 and has grown to become a highly successful company with sales in Australia, New Zealand and the Pacific Islands. BNM sells medical products from vaccines to anesthetics, as well as more typical products such as solid dose tablets and capsules. It also works closely with government health departments in the Pacific Islands. AMCo and BNM have been working together for the past 10 years, as BNM is one of AMCo’s main distributors for medicines in the region.

AMCo is the result of the merger of Amdipharm and the Mercury Pharma Group, both subsidiaries of Channel Islands-based private equity firm Cinven (The Pharma Letter March 15, 2013).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK